Etentamig

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 23:38:04 GMT 2025` Edited by `admin` on `Tue Apr 01 23:38:04 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG4\|KAPPA
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	CO86AOP337
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ABBV-383

Preferred Name

English

Etentamig

Official Name

English

Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383

Common Name

English

immunoglobulin G4-kappa, anti-[Homo sapiens CD3E (CD3 epsilon)] and anti-[Homo sapiens TNFRSF17 (TNF receptor superfamily member 17, BCMA, TNFRSF13A, CD269)], Homo sapiens and humanized monoclonal antibody, bispecific, trivalent; gamma4 heavy chain anti-

Common Name

English

etentamig [INN]

Common Name

English

ETENTAMIG [USAN]

Common Name

English

Anti-BCMA x aCD3 T-BsAb TNB-383B

Common Name

English

Immunoglobulin, anti-(human B-cell maturation antigen) (human monoclonal F1A heavy chain V-D-J region) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin, anti-(human B-cell maturation antigen) (human monoclonal F1A heavy chain

Common Name

English

TNB-383B

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

706319

Created by admin on Tue Apr 01 23:38:04 GMT 2025 , Edited by admin on Tue Apr 01 23:38:04 GMT 2025

Code System Code Type Description

NCI_THESAURUS

C164668

Created by admin on Tue Apr 01 23:38:04 GMT 2025 , Edited by admin on Tue Apr 01 23:38:04 GMT 2025

PRIMARY

USAN

MN-171

Created by admin on Tue Apr 01 23:38:04 GMT 2025 , Edited by admin on Tue Apr 01 23:38:04 GMT 2025

PRIMARY

CAS

2490552-52-6

Created by admin on Tue Apr 01 23:38:04 GMT 2025 , Edited by admin on Tue Apr 01 23:38:04 GMT 2025

PRIMARY

SMS_ID

300000019211

Created by admin on Tue Apr 01 23:38:04 GMT 2025 , Edited by admin on Tue Apr 01 23:38:04 GMT 2025

PRIMARY

FDA UNII

CO86AOP337

Created by admin on Tue Apr 01 23:38:04 GMT 2025 , Edited by admin on Tue Apr 01 23:38:04 GMT 2025

PRIMARY

INN

12522

Created by admin on Tue Apr 01 23:38:04 GMT 2025 , Edited by admin on Tue Apr 01 23:38:04 GMT 2025

PRIMARY

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_300
N	2_322

Related Record Type Details


					ZLW14X2D30

CD3

TARGET -> ACTIVATOR

Amount:


					PK6VHJAIBD

TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17

TARGET->LIGAND

Amount:

Related Record Type Details


					CO86AOP337

Etentamig

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_450] [2_472]	C-TERMINUS	K	Amount:	LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL